Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02885324 · ClinicalTrials.gov registry record · Phase 2
Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children
A Phase 2 study, sponsored by Indiana University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT02885324 is a Phase 2 study that was terminated before completion, run by Indiana University. The registered enrollment target is 4 participants.
The verdict
NCT02885324, a Phase 2 study, was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This pilot will study the feasibility and exploratory efficacy of using Cabozantinib for recurrent or refractory central nervous system tumors for which there are no curative options. Patients will also be followed for safety, time to progression, event free survival and overall survival
Interventions
- DRUG Cabozantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-05-18 |
| Est. Completion | 2020-08-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02885324
The ClinicalTrials.gov registry entry for NCT02885324 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cabozantinib is the first listed.
NCT02885324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02885324 about?
NCT02885324 is a clinical study titled "Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children". This pilot will study the feasibility and exploratory efficacy of using Cabozantinib for recurrent or refractory central nervous system tumors for which there are no curative options. Patients will also be followed for safety, time to progression, event free survival and overall survival
What is the current status of trial NCT02885324?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2017-05-18. Estimated completion is 2020-08-25.
What interventions are being tested in trial NCT02885324?
The interventions under investigation include: Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT02885324?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.